Login to Your Account

Kiadis Pharma files European application for ATIR-101 in HSCT

By Cormac Sheridan
Staff Writer

Wednesday, April 26, 2017

DUBLIN – Kiadis Pharma NV filed an MAA with the EMA for ATIR-101, an adjunctive treatment for patients with hematological malignancies undergoing haploidentical (partially matched) allogeneic HSCT.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription